The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Predicting cachexia development in patients with lung cancer
Puneeth Iyengar, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, notes that identifying patients at risk of developing cachexia is crucial, and recent work on biomarkers and tumor genetics may help predict future weight loss. Understanding the biology of cachexia will enable clinicians to identify patients who may benefit from interventions earlier in the disease course, potentially preventing the development of cachexia. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I mean, that’s a very good point. So, you know, step number one is we need to identify and be able to predict which patients will develop cachexia down the line. And I think some of the work we’re doing with the biomarkers, with the genetics of certain tumors will help us predict future weight loss in patients. But I think that we’re also converging on enough biology so that we can actually start understanding which patients may benefit from cachexia treatments in earlier stages of disease and which ones will not...
Yeah, I mean, that’s a very good point. So, you know, step number one is we need to identify and be able to predict which patients will develop cachexia down the line. And I think some of the work we’re doing with the biomarkers, with the genetics of certain tumors will help us predict future weight loss in patients. But I think that we’re also converging on enough biology so that we can actually start understanding which patients may benefit from cachexia treatments in earlier stages of disease and which ones will not. And so the trials are coming forward. The biology is coming forward. So we’re not only going to be able to identify the patients who will develop cachexia. And if that’s the case, then we can use some of these newer drug approaches to try to intervene earlier in order to suppress the cachexia development into a mature form.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
